Avalo Therapeutics lit up screens this week. Positive Phase 2 LOTUS trial data for AVTX-009 — its lead IL-1β inhibitor targeting hidradenitis suppurativa — sent the stock up 18% on Tuesday and 26% on the week to $16.26. The company simultaneously priced a $375M underwritten offering at $17.75 per share, soaking up fresh capital as the Street scrambled to reprice. Earnings arrive Thursday May 8. The setup is charged.
The short side is caught firmly on the wrong side of the data break. Short interest in AVTX has run hard for months, reaching 30.7% of free float — up 29% in the past month alone. Availability in the borrow market is genuinely constrained; with the lending pool near its tightest reading of the past year, roughly only one share is available for every ten already borrowed. Shorts who need to cover face a crowded exit. Cost to borrow surged 167% over the past week to 1.54%, and while that absolute level remains modest, the speed of the move reflects scrambling demand for borrows ahead of a binary catalyst. The ORTEX short score holds at 78.7 — near the 80th percentile of the universe — which flags this as one of the more structurally shorted names in the biotech space. Days-to-cover runs at 6.1 days per the most recent FINRA fortnightly report.
Options positioning has drifted modestly more defensive into the event. The put/call ratio moved up to 0.92, slightly above its 20-day average of 0.86 but only 0.85 standard deviations above the mean — well within normal range. This isn't a PCR story. The options market is not screaming panic; it's hedging gently while the real action plays out in the borrow market.
Analyst conviction has jumped sharply on the back of the LOTUS readout. Three firms raised price targets on May 6 alone: BTIG lifted its Buy target from $40 to $58, Citizens raised to $62 from $52, and Wedbush moved from $29 to $40. Earlier in April, Wolfe Research and Citizens both initiated coverage with Outperform ratings — a sign that sell-side attention was already building before the data dropped. All 11 analysts covering AVTX carry buy-equivalent ratings. The mean price target now sits around $40, though the freshest and most aggressive calls are running well above that level. Note that the consensus mean figure slightly lags this week's upgrades — directionally the Street has repriced higher. The bull case centres on commercial differentiation in HS, a disease with significant unmet need, and IL-1β's potential to carve out space alongside existing IL-17 inhibitors. Bears point to a 35% probability of approval, competitive pressure in the crowded HS space, and Avalo's pre-profitability cash burn — concerns that the $375M raise directly addresses.
Institutional ownership tells a supportive but not uncomplicatedly bullish story. BVF Partners remains the largest known holder at roughly 9% of shares. FMR (Fidelity) added aggressively in the most recent filing period, more than doubling its position to 7.96%. T. Rowe Price built a new 5.5% stake as recently as March. Millennium Management also added in February. The flip side: OrbiMed trimmed by 162,000 shares in Q4, and Silverarc reduced its position by around 196,000 shares. So the register is tilted toward believers, but not without some distribution at the margin.
Insider sales are the one cautionary note on the ownership side. CFO Chris Sullivan has sold shares consistently through March and April, with multiple transactions totalling roughly $550,000 in proceeds. CMO Mittie Doyle also filed sales in both March and April. The 90-day net insider position is technically a small net inflow once equity awards are counted, but the cash-sales pattern from senior management is worth noting ahead of a high-stakes earnings call. A fresh wave of Form 144 filings on May 6 — covering Sullivan, Doyle, and at least two others — suggests further planned sales.
Past earnings reactions offer limited directional signal. The November 2025 release saw the stock fall 1.3% on the day and 2% over five sessions. The event immediately prior produced a marginal one-day gain but then a 27% five-day rally — likely driven by trial news rather than the print itself. With Q1 2026 results due Thursday and the LOTUS data already public, the actual earnings numbers are secondary. What matters is guidance on the AVTX-009 programme's development timeline, readthrough to Phase 3 planning, and management's framing of how the $375M raise positions the company competitively. Short covering pressure, a freshly loaded register, and newly elevated targets all sit in the balance.
See the live data behind this article on ORTEX.
Open AVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
